Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays

Antiviral Research

Volumn 99, Issue 2, 2013, Pages 119-124

  Ogawa, Eiichi ^a,b   Furusyo, Norihiro ^a,b   Murata, Masayuki ^a   Toyoda, Kazuhiro ^a   Eiraku, Kunimitsu ^a   Shimizu, Motohiro ^a   Harada, Yuji ^a   Mitsumoto, Fujiko ^a   Takayama, Koji ^a   Okada, Kyoko ^a   Kainuma, Mosaburo ^a   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Pegylated interferon; RealTime PCR assay; Ribavirin; Telaprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

HEPATITIS C; PEGYLATED INTERFERON; REALTIME PCR ASSAY; RIBAVIRIN; TELAPREVIR;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84880601180     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.05.002     Document Type: Article

References (27)

1. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 2007, 46:403-410.
2. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B., Hopf U., Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003, 37:600-609.
3. Colucci G., Ferguson J., Harkleroad C., Lee S., Romo D., Soviero S., Thompson J., Velez M., Wang A., Miyahara Y., Young S., Sarrazin C. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the high pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J. Clin. Microbiol. 2007, 45:3600-3695.
4. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2011, 55:245-264.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
7. Furusyo N., Kajiwara E., Takahashi K., Nomura H., Tanabe Y., Masumoto A., Maruyama T., Nakamuta M., Enjoji M., Azuma K., Shimono J., Sakai H., Shimoda S., Hayashi J. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J. Gastroenterol. Hepatol. 2008, 23:1094-1104.
8. Furusyo N., Ogawa E., Sudoh M., Murata M., Ihara T., Hayashi T., Ikezaki H., Hiramine S., Mukae H., Toyoda K., Taniai H., Okada K., Kainuma M., Kajiwara E., Hayashi J. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 2012, 57:1186-1192.
9. Furusyo N., Ogawa E., Nakamuta M., Kajiwara E., Nomura H., Dohmen K., Takahashi K., Satoh T., Azuma K., Kawano A., Tanabe Y., Kotoh K., Shimoda S., Hayashi J. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J. Hepatol. 2013, 10.1016/j.jhep.2013.03.020.
10. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
11. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140:340-355.
12. Ikezaki H., Furusyo N., Ihara T., Hayashi T., Ogawa E., Toyoda K., Taniai H., Kainuma M., Murata M., Hayashi J. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. J. Infect. Chemother. 2011, 17:737-743.
13. Jacobson I.M., McHutchison J.G., Dusheiko G., Di.Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
14. Kumada H., Toyota J., Okanoue T., Chayama K., Tsubouchi H., Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol. 2012, 56:78-84.
15. Moreno C., Deltenre P., Pawlotsky J.M., Henrion J., Adler M., Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J. Hepatol. 2010, 52:25-31.
16. Ogawa E., Furusyo N., Toyoda K., Taniai H., Otaguro S., Kainuma M., Murata M., Sawayama Y., Hayashi J. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol. 2010, 10:38.
17. Ogawa E., Furusyo N., Murata M., Ikezaki H., Ihara T., Hayashi T., Toyoda K., Taniai H., Okada K., Kainuma M., Hayashi J. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J. Hepatol. 2012, 57:534-540.
18. Ogawa E., Furusyo N., Kajiwara E., Takahashi K., Nomura H., Maruyama T., Tanabe Y., Satoh T., Nakamuta M., Kotoh K., Azuma K., Dohmen K., Shimoda S., Hayashi J. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective, multicenter study. J. Hepatol. 2013, 58:495-501.
19. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45:529-538.
20. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C., Reesink H., Zeuzem S., Kwong A.D. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
21. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T., Fried M.W., Adler M., Reesink H.W., Martin M., Sankoh A.J., Adda N., Kauffman R.S., George S., Wright C.I., Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011, 365:1014-1024.
22. Simmonds P., Alberti A., Alter H.J., Bonino F., Bradley D.W., Brechot C., Brouwer J.T., Chan S.W., Chayama K., Chen D.S. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994, 19:1321-1324.
23. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
24. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20.
25. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., Ibranyi E., Weiland O., Noviello S., Brass C., Albrecht J. Efficacy of 24weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006, 44:97-103.
26. Zhou Y., Bartels D.J., Hanzelka B.L., Müh U., Wei Y., Chu H.M., Tigges A.M., Brennan D.L., Rao B.G., Swenson L., Kwong A.D., Lin C. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 2008, 52:110-120.
27. Zitzer H., Heilek G., Truchon K., Susser S., Vermehren J., Sizmann D., Cobb B., Sarrazin C. Second Generation COBAS®AmpliPrep/COBAS® TaqMan® HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J. Clin. Microbiol. 2013, 51:571-577.